Last spring brought alarming reports of the first known case of a germ resistant to colistin, considered an antibiotic of last resort. The bug, a strain of E. coli, was found in a culture taken from a Pennsylvania woman with a urinary tract infection. Thomas Frieden, director of the Centers for Disease Control and Prevention, responded by warning that “the medicine cabinet is empty for some patients,”……read more
June 9, 2016-Selina Koch- A year after raising $22 million in a series A round, Macrolide Pharmaceuticals Inc. has disclosed details of how its antibiotic discovery platform is creating a library of compounds with greater structural diversity than was previously possible – starting with eight simple building blocks….read more
Macrolide Pharmaceuticals Scientific Founder Publishes New Findings in Nature About Groundbreaking Technology for Novel Macrolide Antibiotics
Watertown, MA – May 24, 2016 – Macrolide Pharmaceuticals, Inc., a company with innovative technology to develop novel antibiotics, today announced that a research team led by Macrolide’s scientific founder has published new findings in Nature describing a groundbreaking synthetic chemistry platform…read more
Macrolide was featured this month in AAAS magazine Science article “The Drug Push – fighting drug resistant bacteria”.
As fears of drug resistant bacteria loom, governments try to coax companies back to the field.
Read the article below or download.read more
CAMBRIDGE, Mass. – March 4, 2015 – Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard’s Office of Technology Development…read more
It is becoming increasingly recognized that bacterial antibiotic resistance is outstripping the development of new antibiotic therapeutics, and some authorities even warn of a return to the pre-antibiotic era, where life-threatening infections cannot be successfully treated. Macrolides Macrolides are among the most widely used, most effective and …read more
Welcome to Macrolide Pharmaceuticals. We hope you share our focus on creating new antibiotics to address serious bacterial infections. We believe that the macrolide class is ripe for expansion, and that the Myers technology will allow us to extend the spectrum of the macrolides. We are eager to suggestions, advice…read more